GSK (GSK) Stock Forecast & Price Target

Q: What analysts cover GSK?

GSK has been rated by research analysts at Citigroup , Deutsche Bank Aktiengesellschaft , HSBC , Jefferies Financial Group , Morgan Stanley , Royal Bank Of Canada , and Weiss Ratings in the past 90 days.

$50.80 +0.53 (+1.05%)

As of 08/28/2026 03:58 PM Eastern

Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
2

Hold
6

Buy
2

Based on 10 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 2 have given a sell rating, 6 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for GSK.

Consensus Price Target

$53.00
4.33% Upside

According to the 10 analysts' twelve-month price targets for GSK, the average price target is $53.00. The highest price target for GSK is $53.00, while the lowest price target for GSK is $53.00. The average price target represents a forecasted upside of 4.33% from the current price of $50.80.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

Type	Current Forecast 8/30/25 to 8/30/26	1 Month Ago 7/31/25 to 7/31/26	3 Months Ago 6/1/25 to 6/1/26	1 Year Ago 8/30/24 to 8/30/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	0 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$53.00	$53.00	$53.00	$37.38
Forecasted Upside	4.33% Upside	2.47% Upside	7.65% Upside	-5.81% Downside
Consensus Rating	Hold	Hold	Reduce	Reduce

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Healthcare Companies	Broader Market
Consensus Rating Score	2.10	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	4.33% Upside	841.59% Upside	13.05% Upside
News Sentiment Rating	Positive News See Recent GSK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/25/2026	Morgan Stanley 4 of 5 stars		Reiterated Rating	Underweight
7/30/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Reiterated Rating	Hold
7/29/2026	Weiss Ratings 5 of 5 stars		Downgrade	Buy (B-) ➝ Hold (C+)
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Graham Parry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral
7/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Reduce ➝ Hold
6/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
2/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Gordon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underweight
2/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
11/25/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
Major Buy Alert Issued for August 31st (Ad) Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of August 31st. See which stocks his AI research platform is flagging right now. See which stocks his AI research platform is flagging now
10/30/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wan Nurhayati Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$53.00	+13.21%
6/3/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/15/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$35.25	-1.07%
10/31/2024	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:04 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 24, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

The current stock price is around $108, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
GSK plc has a strong market capitalization of approximately $108.73 billion, indicating a solid position in the market and potential for growth.
The company has a dividend yield of about 3.3%, providing a steady income stream for investors, which is attractive in a low-interest-rate environment.
With institutional investors and hedge funds owning 15.74% of the stock, there is a level of confidence from large investors, which can be a positive signal for retail investors.
GSK plc is focused on science-led pharmaceuticals and vaccines, which positions it well in a growing market, especially with ongoing global health challenges.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

The company has a relatively high price-to-earnings (PE) ratio of 13.97, which may suggest that the stock is overvalued compared to its earnings.
GSK plc's price-to-earnings-growth (PEG) ratio of 3.27 indicates that the stock may not be growing fast enough to justify its current valuation, which could deter growth-focused investors.
Recent changes in institutional holdings show mixed signals, with some hedge funds increasing their stakes while others are making new positions, indicating uncertainty in investor sentiment.
The company has recently cut its dividend, which could be a red flag for income-focused investors who rely on consistent dividend payments.
With a beta of 0.35, GSK plc is less volatile than the market, which may appeal to conservative investors but could also mean less potential for high returns in a bullish market.

GSK Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $53.00, with a high forecast of $53.00 and a low forecast of $53.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 2 sell ratings, 6 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 4.33% based on their 12-month stock forecasts.

Over the previous 90 days, GSK's stock had 2 upgrades and 2 downgrades by analysts.

GSK has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, HSBC, Jefferies Financial Group, Morgan Stanley, Royal Bank Of Canada, and Weiss Ratings in the past 90 days.

Analysts like GSK less than other "healthcare" companies. The consensus rating score for GSK is 2.10 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

MarketBeat monitors more than a dozen sources for GSK analyst ratings, with the most recent rating issued on 8/25/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target